| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1050301954 |
| P356 | DOI | 10.1007/S00467-004-1680-0 |
| P698 | PubMed publication ID | 15549408 |
| P2093 | author name string | Stefan Worgall | |
| P2860 | cites work | Evidence that bone morphogenetic protein 4 has multiple biological functions during kidney and urinary tract development | Q24297582 |
| Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease | Q28143064 | ||
| LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 | Q28210584 | ||
| Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer | Q28211178 | ||
| Transcription start regions in the human genome are favored targets for MLV integration | Q29618456 | ||
| A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency | Q33340517 | ||
| Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease | Q33869745 | ||
| Molecular biology of adeno-associated viruses | Q34002311 | ||
| Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain | Q34142832 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Antivector and antitransgene host responses in gene therapy. | Q34183384 | ||
| Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates | Q34220503 | ||
| High-capacity 'gutless' adenoviral vectors. | Q34431803 | ||
| Hepatic and renal differentiation from blood-borne stem cells. | Q34658441 | ||
| Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors | Q34658448 | ||
| Therapeutic globin gene delivery using lentiviral vectors. | Q34999167 | ||
| Adeno-associated viruses undergo substantial evolution in primates during natural infections | Q35022838 | ||
| Current status of gene therapy for inherited lung diseases | Q35043830 | ||
| Gene delivery using herpes simplex virus vectors | Q35062264 | ||
| Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia | Q35069562 | ||
| Gene therapy using an adenovirus vector for apoptosis-related genes is a highly effective therapeutic modality for killing glioma cells | Q35090824 | ||
| Progress and problems with the use of viral vectors for gene therapy | Q35120176 | ||
| Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy | Q35131218 | ||
| Bone marrow stem cells contribute to healing of the kidney | Q35133240 | ||
| Renal gene transfer: nonviral approaches | Q35141421 | ||
| Applications of gene therapy to kidney disease | Q35157973 | ||
| From virus evolution to vector revolution: use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy | Q35180997 | ||
| Targeting retroviral and lentiviral vectors. | Q35204394 | ||
| Gene therapy for human malignant brain tumors. | Q35210470 | ||
| Comparison of replication-selective, oncolytic viruses for the treatment of human cancers. | Q35545265 | ||
| AAV-based gene transfer | Q35545274 | ||
| Targeting survival: integration site selection by retroviruses and LTR-retrotransposons | Q35563809 | ||
| AAV-mediated gene therapy for hemophilia | Q35577203 | ||
| Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors | Q35640271 | ||
| Gene delivery by lentivirus vectors an overview. | Q35670108 | ||
| Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency | Q35676196 | ||
| Gene therapy in renal diseases. | Q35746821 | ||
| Prospects and implications of using chromatin insulators in gene therapy and transgenesis | Q35819847 | ||
| Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses | Q36954135 | ||
| Molecular therapy for renal diseases | Q39182534 | ||
| Transfer of genes to humans: early lessons and obstacles to success | Q40418899 | ||
| AAV-mediated gene transfer to skeletal muscle. | Q40588802 | ||
| The basic science of gene therapy | Q40907463 | ||
| A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. | Q41203495 | ||
| Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 | ||
| Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions | Q43846711 | ||
| Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning | Q44044895 | ||
| Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. | Q44266290 | ||
| Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults | Q45676046 | ||
| Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity | Q45698037 | ||
| Transduction of renal cells in vitro and in vivo by adeno-associated virus gene therapy vectors. | Q45747405 | ||
| A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency | Q45857796 | ||
| Gene therapy death prompts review of adenovirus vector | Q45864618 | ||
| Clinical gene transfer studies for hemophilia B. | Q45875059 | ||
| Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation | Q45879591 | ||
| Gene therapy with recombinant adenovirus vectors: evaluation of the host immune response | Q45882846 | ||
| Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy | Q45884700 | ||
| Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. | Q45885499 | ||
| Fas ligand gene transfer to renal allografts in rats: effects on allograft survival | Q46449268 | ||
| Favorable effect of cotransfection with TGF-beta and CTLA4Ig of the donor kidney on allograft survival | Q47841574 | ||
| Gene delivery using human cord blood-derived CD34+cells into inflamed glomeruli in NOD/SCID mice | Q47860423 | ||
| CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft | Q56906071 | ||
| Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice | Q64377665 | ||
| Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung | Q64382719 | ||
| Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis | Q71660966 | ||
| Genetically modified bone marrow-derived vehicle cells site specifically deliver an anti-inflammatory cytokine to inflamed interstitium of obstructive nephropathy | Q73311951 | ||
| Human gene therapy | Q95799789 | ||
| P433 | issue | 2 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 118-124 | |
| P577 | publication date | 2004-11-10 | |
| P1433 | published in | Pediatric Nephrology | Q15749796 |
| P1476 | title | A realistic chance for gene therapy in the near future | |
| P478 | volume | 20 |
| Q34450895 | Acinar-to-ductal metaplasia induced by adenovirus-mediated pancreatic expression of Isl1. |
| Q35791792 | Adeno-Associated Virus-Mediated Gene Transfer to Renal Tubule Cells via a Retrograde Ureteral Approach |
| Q36600228 | Combining cell therapy and nanotechnology |
| Q36418370 | Gene therapeutics for periodontal regenerative medicine. |
| Q35770271 | Gene therapy of benign gynecological diseases |
| Q36583746 | Growth factor delivery for oral and periodontal tissue engineering |
| Q41853299 | Nucleofection mediates high-efficiency stable gene knockdown and transgene expression in human embryonic stem cells |
| Q39827069 | SHARP-2 gene silencing by lentiviral-based short hairpin RNA interference prolonged rat kidney transplant recipients' survival time |
| Q36972714 | The state of the art of adeno-associated virus-based vectors in gene therapy |
Search more.